Page 6 - Merck Sharp News Today

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety...

CT141 mRNA-4157 Individualized Neoantigen Therapy +...

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer. Patients w...

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the...

English Swedish ...

TME PHARMA RECEIVES US FDA FAST TRACK DESIGNATION FOR LEAD ASSET NOX-A12 IN BRAIN CANCER Fast Track designation awarded by the...

TME PHARMA RECEIVES US FDA FAST TRACK DESIGNATION FOR LEAD ASSET NOX-A12 IN BRAIN CANCER Fast Track designation awarded by the...

Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in glioblastoma and could support an accelerated pathway to US regulatory...

- Data for masked anti-CTLA-4 SAFEbody® ADG126 highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable colorectal cancer with higher, more...

Harpoon Therapeutics (NASDAQ:HARP – Get Free Report) and LianBio (NASDAQ:LIAN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Profitability This table compares Harpoon Therapeutics and LianBio’s […]